首页> 外文期刊>Radiation oncology >Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer
【24h】

Whole brain radiotherapy plus simultaneous in-field boost with image guided intensity-modulated radiotherapy for brain metastases of non-small cell lung cancer

机译:全脑放疗加同时场内增强结合影像引导的调强放射治疗非小细胞肺癌的脑转移

获取原文
           

摘要

Background Whole brain radiotherapy (WBRT) plus sequential focal radiation boost is a commonly used therapeutic strategy for patients with brain metastases. However, recent reports on WBRT plus simultaneous in-field boost (SIB) also showed promising outcomes. The objective of present study is to retrospectively evaluate the efficacy and toxicities of WBRT plus SIB with image guided intensity-modulated radiotherapy (IG-IMRT) for inoperable brain metastases of NSCLC. Methods Twenty-nine NSCLC patients with 87 inoperable brain metastases were included in this retrospective study. All patients received WBRT at a dose of 40 Gy/20 f, and SIB boost with IG-IMRT at a dose of 20 Gy/5 f concurrent with WBRT in the fourth week. Prior to each fraction of IG-IMRT boost, on-line positioning verification and correction were used to ensure that the set-up errors were within 2?mm by cone beam computed tomography in all patients. Results The one-year intracranial control rate, local brain failure rate, and distant brain failure rate were 62.9%, 13.8%, and 19.2%, respectively. The two-year intracranial control rate, local brain failure rate, and distant brain failure rate were 42.5%, 30.9%, and 36.4%, respectively. Both median intracranial progression-free survival and median survival were 10?months. Six-month, one-year, and two-year survival rates were 65.5%, 41.4%, and 13.8%, corresponding to 62.1%, 41.4%, and 10.3% of intracranial progression-free survival rates. Patients with Score Index for Radiosurgery in Brain Metastases (SIR) >5, number of intracranial lesions Conclusions WBRT plus SIB with IG-IMRT is a tolerable and effective treatment for NSCLC patients with inoperable brain metastases. However, the results of present study need to be examined by the prospective investigations.
机译:背景技术全脑放疗(WBRT)加上顺序聚焦放疗是脑转移患者的常用治疗策略。但是,最近有关WBRT加上同步现场增强(SIB)的报告也显示出可喜的结果。本研究的目的是回顾性评估WBRT联合SIB结合图像引导强度调制放射疗法(IG-IMRT)对非手术性NSCLC脑转移的疗效和毒性。方法回顾性研究29例NSCLC患者,其中87例无法手术的脑转移。所有患者均以40 Gy / 20 f的剂量接受WBRT,并在第4周以IG-IMRT以20 Gy / 5 f的剂量进行IBB强化,同时进行WBRT。在进行IG-IMRT增强的每个部分之前,通过锥形束计算机断层扫描对所有患者进行在线定位验证和校正,以确保设置误差在2?mm以内。结果一年的颅内控制率,局部脑衰竭率和远距脑衰竭率分别为62.9%,13.8%和19.2%。两年的颅内控制率,局部脑衰竭率和远距脑衰竭率分别为42.5%,30.9%和36.4%。中位颅内无进展生存期和中位生存期均为10个月。六个月,一年和两年生存率分别为65.5%,41.4%和13.8%,分别相当于颅内无进展生存率的62.1%,41.4%和10.3%。脑转移放射指数(SIR)> 5的患者,颅内病变数目结论结论WBRT加SIB联合IG-IMRT对不能手术的NSCLC患者是一种可以耐受且有效的治疗方法。但是,本研究的结果需要通过前瞻性研究来检验。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号